MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)*
Organization & Developments: 4D Molecular Therapeutics
Parents
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)*
Children
*FDMT develops therapies in three disease areas - ophthalmology, cardiology and pulmonology - using its AAV vector platform.
2023: 4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile_ seekingalpha.com
2023: 4D Molecular Therapeutics: Some Failures, A Few Key Successes
2024: 4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
2024: 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
2024: 4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution_ seekingalpha.com
2024: 4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
2024: 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
2024: 4D Molecular Therapeutics' SWOT analysis: gene therapy stock poised for growth amid challenge
2024: 4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
2025: 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
2025: 4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline
Jumps
Finance & Acquisitions: 4D Molecular Therapeutics
Key People: 4D Molecular Therapeutics